文献速递乳腺癌

抗Trop-2抗体药物偶联物Sacituzumab Govitecan(IMMU-132)在经重度治疗的转移性三阴性乳腺癌患者中的疗效与安全性

Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
PubMed 文献 · J Clin Oncol · 2017-03-14

这项单臂多中心试验评估了Sacituzumab Govitecan在69例经重度治疗的复发/难治性转移性三阴性乳腺癌患者中的疗效与安全性,确认的客观缓解率为30%,中位缓解持续时间8.9个月,中位无进展生存期6.0个月,中位总生存期16.6个月,常见≥3级不良事件为中性粒细胞减少(39%)。

要点

  • 确认的客观缓解率为30%,其中部分缓解19例、完全缓解2例
  • 中位缓解持续时间8.9个月(95%CI 6.1至11.3),中位起效时间1.9个月
  • ≥3级不良事件包括中性粒细胞减少39%、白细胞减少16%、贫血14%、腹泻13%

核心结论

  • Sacituzumab Govitecan耐受性良好,在经重度治疗的转移性三阴性乳腺癌患者中诱导了早期且持久的缓解。
  • Trop-2作为治疗靶点和预测性生物标志物值得进一步研究。

研究设计与样本

  • 单臂、多中心试验,评估Sacituzumab Govitecan在复发/难治性转移性三阴性乳腺癌患者中的疗效与安全性。
  • 给药方案为10 mg/kg起始剂量,在21天重复周期的第1天和第8天给药。
  • 主要终点为安全性和客观缓解率;次要终点为无进展生存期和总生存期。
  • 共纳入69例患者,自诊断以来接受过中位五种既往治疗(范围,一种至12种)。

主要发现

  • 确认的客观缓解率为30%(部分缓解19例,完全缓解2例),中位缓解持续时间为8.9个月(95%CI,6.1至11.3),临床获益率(完全缓解+部分缓解+疾病稳定≥6个月)为46%。
  • 缓解出现较早,中位起效时间为1.9个月。
  • 中位无进展生存期为6.0个月(95%CI,5.0至7.3),中位总生存期为16.6个月(95%CI,11.1至20.6)。
  • ≥3级不良事件包括中性粒细胞减少(39%)、白细胞减少(16%)、贫血(14%)和腹泻(13%);发热性中性粒细胞减少发生率为7%。
  • 多数存档肿瘤标本(88%)经免疫组化检测Trop-2呈中度至强阳性;尽管反复周期给药,未检测到针对抗体药物偶联物或抗体的中和抗体。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose Trop-2, expressed in most triple-negative breast cancers (TNBCs), may be a potential target for antibody-drug conjugates. Sacituzumab govitecan, an antibody-drug conjugate, targets Trop-2 for the selective delivery of SN-38, the active metabolite of irinotecan. Patients and Methods We evaluated sacituzumab govitecan in a single-arm, multicenter trial in patients with relapsed/refractory metastatic TNBC who received a 10 mg/kg starting dose on days 1 and 8 of 21-day repeated cycles. The primary end points were safety and objective response rate; secondary end points were progression-free survival and overall survival. Results In 69 patients who received a median of five prior therapies (range, one to 12) since diagnosis, the confirmed objective response rate was 30% (partial response, n = 19; complete response, n = 2), the median response duration was 8.9 (95% CI, 6.1 to 11.3) months, and the clinical benefit rate (complete response + partial response + stable disease ≥ 6 months) was 46%. These responses occurred early, with a median onset of 1.9 months. Median progression-free survival was 6.0 (95% CI, 5.0 to 7.3) months, and median overall survival was 16.6 (95% CI, 11.1 to 20.6) months. Grade ≥ 3 adverse events included neutropenia (39%), leukopenia (16%), anemia (14%), and diarrhea (13%); the incidence of febrile neutropenia was 7%. The majority of archival tumor specimens (88%) were moderately to strongly positive for Trop-2 by immunohistochemistry. No neutralizing antibodies to the ADC or antibody were detected, despite repeated cycles developed. Conclusion Sacituzumab govitecan was well tolerated and induced early and durable responses in heavily pretreated patients with metastatic TNBC. As a therapeutic target and predictive biomarker, Trop-2 warrants further research.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Bardia A, Mayer IA, Diamond JR, et al. Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer. J Clin Oncol. 2017. PMID: 28291390. doi:10.1200/JCO.2016.70.8297

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。